Imaging
Augmenix raises $11M for surgical hydrogels as Varian’s purchase option expires
Massachusetts-based Augmenix is hoping it can make it to the U.S. market with the $10.8 million funding round it just closed, the company said this month.
Elekta eyes Turkish radiology market with acquisition of Mesi Medikal
Ulthera pulls $86M IPO in favor of $600M merger
Arizona device maker Ulthera is ditching its planned initial public offering in favor of a $600 million merger with larger aesthetics company Merz Inc., according to an SEC filing.
Boston Scientific aims to simplify intravascular imaging with Polaris
Boston Scientific (NYSE:BSX) today announced the commercial launch of its Polaris imaging software, an upgrade to the company’s iLab system that aims to make intravascular imaging simpler and more powerful.
SEC dings Misonix investor relations exec for insider trading
DICOM Grid raises $6M for cloud-based medical imaging systems
Vermont medical imaging services provider DICOM Grid today announced that it raised $6 million in an inside funding round, with investment coming from Canaan Partners, CHL Medical Partners, the Mayo Clinic and several individual investors.
Veran Medical nears close of $7.5M round in support of airway imaging
Veran Medical Technologies is on the verge of closing yet another fundraising round in support of its electromagnetic airway mapping system, with just about $1 million to go.
InSightec seeks $50M for ultrasound tumor therapy
Israel-based InSightec is looking for a few investors to jump in on its $50 million Series D funding round, saying it’ll use the funds to boost commercial efforts for its non-invasive tumor-targeting ultrasound therapy.
York Capital Management is already lined up to take a chunk out of the $50 million, leaving "limited time" for other prospective funders to jump in on the initial round or to expand fundraising to $62.5 million, InSightec said.
Press Release: EDAP completes FDA inspection of manufacturing site
LYON, France — EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that the U.S. Food and Drug Administration (FDA) concluded its routine inspection of EDAP’s manufacturing site with no findings nor issuance of Form 483 observations.